Shots:
- Arcus has reported data from Arm A1 (n=41) of the P-II (EDGE-Gastric) trial assessing domvanalimab (1600mg, IV, Q4W) + Yutuo (480mg, IV, Q4W) & CT in pts with locally advanced unresectable or metastatic G/GEJ or esophageal adenocarcinoma
- As of Mar 3, 2025 (mFU of 26.4mos.), pts showed 24mos. OS rate of 50.2% (mOS: 26.7mos.) & PFS of 25.9% (mPFS: 12.9mos.), with cORR of 59% in the overall population
- In PD-L1+ (≥1%; n=29) & PD-L1 high (≥5%; n=16) pts, cORR was 62% & 69%, 24mos. PFS rates of 24.9% & 31.3% (mPFS: 13.2 & 14.5mos.), & OS rates of 53.8% & 56.3% (mOS: 26.7mos. & not reached), respectively; data to be presented at ESMO’25
Ref: Arcus Biosciences | Image: Arcus Biosciences | Press Release
Related News:- Ono Pharmaceutical Reports the P-II (ONO-4578-08) Trial Findings of ONO-4578 in Gastric or Gastroesophageal Junction (G/GEJ) Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
